Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …

Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …

B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates
multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or …

T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …

Immune cell engagers are engineered antibodies with at least one arm binding a tumor-
associated antigen and at least another one directed against an activating receptor in …

Bispecific antibodies targeting GPRC5D demonstrated promising efficacy in multiple
myeloma, but acquired resistance usually occurs within a few months. Using a single …

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …

Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …